查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1339165

品牌仿製药市场,份额,规模,趋势,行业分析报告:按药物类别,应用,给药途径,分销管道,地区,细分市场,预测2023-2032 年

Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2个工作天内

价格

根据 Polaris Market Research 的一项新研究，到 2032 年，全球品牌仿製药市场预计将达到 4,108.6 亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

糖尿病、高血压和癌症等慢性病发病率的上升推动了对药品的需求。品牌仿製药正在成为慢性病患者的热门选择，因为它们提供了比昂贵的品牌药更实惠的替代品。仿製药的传播也是推动品牌仿製药市场的因素之一。

仿製药已越来越被医生和患者接受，因为它们在品质、安全性和有效性方面可与品牌药相媲美。政府促进使用仿製药以降低整体医疗成本的措施也促进了品牌仿製药市场的成长。世界各国政府正在推广使用仿製药，以降低医疗保健成本，并使患者更容易负担得起药物。

传染病和非传染性疾病负担的增加以及老年人口的增加预计将对医疗保健行业的成长产生积极影响。糖尿病、高血压和肥胖等慢性病在世界各地变得越来越普遍，而人口老化更容易患上这些疾病。

因此，对医疗保健服务和产品（包括品牌仿製药）的需求预计将大幅增加。例如，据美国癌症研究所估计，2021 年全球将有 3,700 万癌症患者。糖尿病是一种慢性疾病，需要持续的治疗和管理。品牌仿製药正在成为糖尿病患者的热门选择，因为它们提供了比昂贵的品牌药物更实惠的替代品。

高血压也是一种慢性病，多发于中老年人。据世界卫生组织 (WHO) 称，高血压影响全球 10 亿人，预计到 2025 年将增加到 15 亿。品牌仿製药为高血压提供了负担得起的治疗选择，并正在推动市场需求。

品牌仿製药市场报告亮点

由于老年人心臟病发病率的增加以及更便宜的替代品的出现，抗高血压药物占据了最大份额

由于口服药物具有护理经验少、患者接受度高等优点，口服药物市场占有很大的市场份额。

零售药局销售份额预计扩大，主要由于新兴市场零售药局数量增加

由于对低成本药物的偏好日益增加，预计亚太地区在研究期间将出现高成长率

目录

第 1 章 简介

第二章执行摘要

第三章研究方法论

第四章全球品牌仿製药市场洞察

  • 品牌仿製药市场－通路快照
  • 品牌学名药市场动态
    • 驱动因素和机遇
      • 慢性病患病率增加
      • 过期专利增加
    • 限制因素和挑战
      • 严格的监管政策和品牌药的巨大竞争
  • PESTEL 分析
  • 品牌仿製药市场通路的趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第五章全球品牌仿製药市场（依药物类别）

  • 主要发现
  • 介绍
  • 烷基化剂
  • 抗代谢药
  • 激素
  • 降压药
  • 降血脂药
  • 抗忧郁药
  • 抗精神病药
  • 抗癫痫药
  • 其他

第六章 全球品牌仿製药市场（按应用）

  • 主要发现
  • 介绍
  • 肿瘤学
  • 心血管疾病
  • 神经系统疾病
  • 消化系统疾病
  • 皮肤病
  • 急性和慢性疼痛
  • 其他

第七章 全球品牌仿製药市场（依通路）

  • 主要发现
  • 介绍
  • 当地的
  • 口服
  • 肠外

第八章全球品牌仿製药市场（按地区）

  • 主要发现
  • 介绍
    • 品牌仿製药市场评估（按地区），2019-2032
  • 品牌仿製药市场 - 北美
    • 北美：品牌仿製药市场，按药物类别划分，2019-2032 年
    • 北美：品牌仿製药市场，依通路划分，2019-2032 年
    • 北美：品牌仿製药市场，按应用划分，2019-2032 年
    • 品牌仿製药市场 - 美国
    • 品牌仿製药市场 - 加拿大
  • 品牌仿製药市场 - 欧洲
    • 欧洲：品牌仿製药市场，依药物类别，2019-2032
    • 欧洲：品牌仿製药市场，依通路划分，2019-2032 年
    • 欧洲：品牌仿製药市场，依应用划分，2019-2032
    • 品牌学名药市场－英国
    • 品牌仿製药市场－法国
    • 品牌仿製药市场 - 德国
    • 品牌仿製药市场—义大利
    • 品牌学名药市场－西班牙
    • 品牌仿製药市场－荷兰
    • 品牌仿製药市场 - 俄罗斯
  • 品牌仿製药市场 – 亚太地区
    • 亚太地区：品牌仿製药市场，依药物类别划分，2019-2032 年
    • 亚太地区：品牌仿製药市场，依通路划分，2019-2032 年
    • 亚太地区：品牌仿製药市场，按应用划分，2019-2032 年
    • 品牌仿製药市场 - 中国
    • 品牌仿製药市场—印度
    • 品牌学名药市场－马来西亚
    • 品牌仿製药市场 - 日本
    • 品牌仿製药市场 - 印度尼西亚
    • 品牌学名药市场 - 韩国
  • 品牌仿製药市场 - 中东和非洲
    • 中东和非洲：品牌仿製药市场，按药物类别，2019-2032 年
    • 中东和非洲：品牌仿製药市场，按分销管道划分，2019-2032 年
    • 中东和非洲：品牌仿製药市场，按应用划分，2019-2032 年
    • 品牌学名药市场－沙乌地阿拉伯
    • 品牌学名药市场－阿拉伯联合大公国
    • 品牌学名药市场－以色列
    • 品牌仿製药市场—南非
  • 品牌仿製药市场 - 拉丁美洲
    • 拉丁美洲：品牌仿製药市场，按药物类别划分，2019-2032 年
    • 拉丁美洲：品牌仿製药市场，按分销管道划分，2019-2032 年
    • 拉丁美洲：品牌仿製药市场，按应用划分，2019-2032 年
    • 品牌仿製药市场—墨西哥
    • 品牌仿製药市场—巴西
    • 品牌仿製药市场—阿根廷

第9章 竞争格局

  • 扩张和收购分析
    • 扩张
    • 获得
  • 伙伴关係/协作/协议/揭露

第十章公司简介

  • Teva Pharmaceutical
  • Lupin
  • Sanofi
  • Sun Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Endo International
  • GlaxoSmithKline
  • Pfizer
  • Apotex
  • Viatris, Inc.
Product Code: PM3545

The global branded generics market size is expected to reach USD 410.86 billion by 2032, according to a new study by Polaris Market Research. The report "Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing rates of chronic diseases such as diabetes, hypertension, and cancer are driving the demand for drugs. Branded generics are becoming a popular choice for patients suffering from chronic illnesses as they offer a more affordable alternative to expensive brand-name drugs. The widespread use of generic drugs is another factor driving the branded generics market.

Generic drugs have become more widely accepted by both physicians and patients as they are equivalent in quality, safety, and efficacy to their brand-name counterparts. Government initiatives promoting the use of generic drugs to reduce overall healthcare costs are also driving the growth of the branded generics market. Governments worldwide are promoting the use of generic drugs to lower healthcare costs and increase access to affordable medicines for patients.

Growing burden of infectious and non-infectious diseases, along with the rising geriatric population, is expected to have a positive impact on the healthcare industry's growth. Chronic diseases such as diabetes, hypertension, and obesity are becoming more prevalent worldwide, and the geriatric population is more susceptible to these diseases.

As a result, the demand for healthcare services and products, including branded generics, is expected to increase significantly. According to an NCBI article, there were 537 million patients suffering from diabetes globally in 2021. Diabetes is a chronic disease that requires ongoing medical care and management. Branded generics are becoming a popular choice for diabetic patients as they offer a more affordable alternative to expensive brand-name drugs.

Hypertension is another chronic disease that is prevalent among the geriatric population. According to the World Health Organization (WHO), hypertension impacts 1 Bn people globally, and this is expected to rise to 1.5 Bn, by 2025. Branded generics offer an affordable treatment option for hypertension, which is driving their demand in the market.

Branded Generics Market Report Highlights

Anti-hypersensitive segment accounted for the largest share, owing to rise in cardiac ailments among geriatrics, and availability of low-cost alternatives

Oral segment accounted for the larger market share, owing to the advantages of oral based drug administration with minimal nursing experience, with high accept patient acceptability

Retail pharmacy is projected to experience larger revenue share, primarily due to increase in number of retail pharmacies in the developed markets

APAC is projected to register a higher growth rate in the study period, due to increase in preference of low-cost medicines

The global players include: Teva Pharmaceutical, Lupin, Sanofi, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Endo International, GlaxoSmithKline, Pfizer, Apotex, and Viatris, Inc.

Polaris Market Research has segmented the branded generics market report based on drug class, application, route of administration, by distribution channel, and region:

Branded Generics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-Hypertensive
  • Lipid Lowering Drugs
  • Anti-Depressants
  • Anti-Psychotics
  • Anti-Epileptics
  • Others

Branded Generics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Gastrointestinal Diseases
  • Dermatological Diseases
  • Acute and Chronic Pain
  • Others

Branded Generics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Topical
  • Oral
  • Parenteral
  • Others

Branded Generics, Distribution Channel Industry Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Branded Generics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Distribution Channels
    • 3.2.1. Primary Distribution Channels
    • 3.2.2. Secondary Distribution Channels

4. Global Branded Generics Market Insights

  • 4.1. Branded Generics Market - Distribution Channel Snapshot
  • 4.2. Branded Generics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence rate of chronic diseases
      • 4.2.1.2. Rising number of expired patents
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Strict regulatory policies and huge competition from branded drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Branded Generics Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Branded Generics Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Alkylating Agents
    • 5.3.1. Global Branded Generics Market, by Alkylating Agents, by Region, 2019-2032 (USD Billion)
  • 5.4. Antimetabolites
    • 5.4.1. Global Branded Generics Market, by Antimetabolites, by Region, 2019-2032 (USD Billion)
  • 5.5. Hormones
    • 5.5.1. Global Branded Generics Market, by Hormones, by Region, 2019-2032 (USD Billion)
  • 5.6. Anti-Hypertensive
    • 5.6.1. Global Branded Generics Market, by Anti-Hypertensive, by Region, 2019-2032 (USD Billion)
  • 5.7. Lipid Lowering Drugs
    • 5.7.1. Global Branded Generics Market, by Lipid Lowering Drugs, by Region, 2019-2032 (USD Billion)
  • 5.8. Anti-Depressants
    • 5.8.1. Global Branded Generics Market, by Anti-Depressants, by Region, 2019-2032 (USD Billion)
  • 5.9. Anti-Psychotics
    • 5.9.1. Global Branded Generics Market, by Anti-Psychotics, by Region, 2019-2032 (USD Billion)
  • 5.10. Anti-Epileptics
    • 5.10.1. Global Branded Generics Market, by Anti-Epileptics, by Region, 2019-2032 (USD Billion)
  • 5.11. Others
    • 5.11.1. Global Branded Generics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Branded Generics Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Branded Generics Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Global Branded Generics Market, by Cardiovascular Diseases, by Region, 2019-2032 (USD Billion)
  • 6.5. Neurological Diseases
    • 6.5.1. Global Branded Generics Market, by Neurological Diseases, by Region, 2019-2032 (USD Billion)
  • 6.6. Gastrointestinal Diseases
    • 6.6.1. Global Branded Generics Market, by Gastrointestinal Diseases, by Region, 2019-2032 (USD Billion)
  • 6.8. Dermatological Diseases
    • 6.8.1. Global Branded Generics Market, by Dermatological Diseases, by Region, 2019-2032 (USD Billion)
  • 6.9. Acute and Chronic Pain
    • 6.9.1. Global Branded Generics Market, by Acute and Chronic Pain, by Region, 2019-2032 (USD Billion)
  • 6.10. Others
    • 6.10.1. Global Branded Generics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Branded Generics Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Topical
    • 7.3.1. Global Branded Generics Market, by Topical, By Region, 2019-2032 (USD Billion)
  • 7.4. Oral
    • 7.4.1. Global Branded Generics Market, by Oral, By Region, 2019-2032 (USD Billion)
  • 7.5. Parenteral
    • 7.5.1. Global Branded Generics Market, by Parenteral, By Region, 2019-2032 (USD Billion)
  • 7.6. Oral
    • 7.6.1. Global Branded Generics Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Branded Generics Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Branded Generics Market - North America
    • 8.3.1. North America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Branded Generics Market - U.S.
      • 8.3.4.1. U.S.: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Branded Generics Market - Canada
      • 8.3.5.1. Canada: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Branded Generics Market - Europe
    • 8.4.1. Europe: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Branded Generics Market - UK
      • 8.4.4.1. UK: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Branded Generics Market - France
      • 8.4.5.1. France: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Branded Generics Market - Germany
      • 8.4.6.1. Germany: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Branded Generics Market - Italy
      • 8.4.7.1. Italy: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Branded Generics Market - Spain
      • 8.4.8.1. Spain: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Branded Generics Market - Netherlands
      • 8.4.9.1. Netherlands: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Branded Generics Market - Russia
      • 8.4.10.1. Russia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Branded Generics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Branded Generics Market - China
      • 8.5.4.1. China: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Branded Generics Market - India
      • 8.5.5.1. India: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Branded Generics Market - Malaysia
      • 8.5.6.1. Malaysia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Branded Generics Market - Japan
      • 8.5.7.1. Japan: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Branded Generics Market - Indonesia
      • 8.5.8.1. Indonesia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Branded Generics Market - South Korea
      • 8.5.9.1. South Korea: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Branded Generics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Branded Generics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Branded Generics Market - UAE
      • 8.6.5.1. UAE: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Branded Generics Market - Israel
      • 8.6.6.1. Israel: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Branded Generics Market - South Africa
      • 8.6.7.1. South Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Branded Generics Market - Latin America
    • 8.7.1. Latin America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Branded Generics Market - Mexico
      • 8.7.4.1. Mexico: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Branded Generics Market - Brazil
      • 8.7.5.1. Brazil: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Branded Generics Market - Argentina
      • 8.7.6.1. Argentina: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Branded Generics Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Teva Pharmaceutical
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Class Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Lupin
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Class Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Sanofi
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Class Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Sun Pharmaceutical Industries
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Class Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Dr. Reddy's Laboratories
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Class Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Endo International
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Class Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GlaxoSmithKline
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Class Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Class Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Apotex
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Drug Class Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Viatris, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Drug Class Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Branded Generics Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Branded Generics Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Branded Generics Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Branded Generics Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Branded Generics Market